CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
3.62 EUR
+0 (+0.11%)
5CV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. 5CV has an average financial health and profitability rating. 5CV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year 5CV was profitable.
5CV had a negative operating cash flow in the past year.
In the past 5 years 5CV reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.31%, 5CV belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.79%, 5CV belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
With an excellent Return On Invested Capital value of 14.12%, 5CV belongs to the best of the industry, outperforming 90.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
5CV has a Profit Margin of 182.11%. This is amongst the best in the industry. 5CV outperforms 97.53% of its industry peers.
5CV has a Operating Margin of 212.01%. This is amongst the best in the industry. 5CV outperforms 98.77% of its industry peers.
5CV has a better Gross Margin (93.01%) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
5CV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, 5CV has about the same amount of shares outstanding.
The number of shares outstanding for 5CV has been increased compared to 5 years ago.
The debt/assets ratio for 5CV has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.04 indicates that 5CV is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.04, 5CV is in the better half of the industry, outperforming 75.31% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that 5CV is not too dependend on debt financing.
5CV's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. 5CV outperforms 67.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.04 |
ROIC/WACC1.97
WACC7.18%
2.3 Liquidity
5CV has a Current Ratio of 3.70. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
5CV's Current ratio of 3.70 is fine compared to the rest of the industry. 5CV outperforms 69.14% of its industry peers.
5CV has a Quick Ratio of 3.69. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
5CV's Quick ratio of 3.69 is fine compared to the rest of the industry. 5CV outperforms 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
5CV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.83%, which is quite impressive.
The Revenue for 5CV has decreased by -86.98% in the past year. This is quite bad
Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
Based on estimates for the next years, 5CV will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
The Revenue is expected to decrease by -10.88% on average over the next years. This is quite bad
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.24, the valuation of 5CV can be described as very cheap.
Based on the Price/Earnings ratio, 5CV is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.77, 5CV is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.24 | ||
| Fwd PE | N/A |
4.2 Price Multiples
5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 95.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.55 |
4.3 Compensation for Growth
A cheap valuation may be justified as 5CV's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:5CV (12/30/2025, 7:00:00 PM)
3.62
+0 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap815.12M
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts73.33
Price Target4.02 (11.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)557.4%
Min EPS beat(2)-39.67%
Max EPS beat(2)1154.47%
EPS beat(4)2
Avg EPS beat(4)282.88%
Min EPS beat(4)-39.67%
Max EPS beat(4)1154.47%
EPS beat(8)3
Avg EPS beat(8)141.82%
EPS beat(12)5
Avg EPS beat(12)87.36%
EPS beat(16)8
Avg EPS beat(16)76.39%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-2.59%
PT rev (3m)-4.38%
EPS NQ rev (1m)966.6%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)9.31%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)33.33%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)19.7%
Revenue NY rev (3m)3.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.24 | ||
| Fwd PE | N/A | ||
| P/S | 11.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.94 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | 2.55 |
EPS(TTM)0.58
EY16.02%
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.31
BVpS3.87
TBVpS3.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.04 |
F-Score3
WACC7.18%
ROIC/WACC1.97
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
Can you provide the valuation status for CUREVAC NV?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
What is the profitability of 5CV stock?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.